Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA, Orexigen Discussing CV Risk Study For Weight-Loss Drug Contrave

This article was originally published in The Pink Sheet Daily

Executive Summary

Timing of the study to be discussed at Dec. 7 advisory committee meeting.

You may also be interested in...



FDA Panel Backs Approval Of Takeda/Orexigen's Obesity Drug Contrave

The promise of a randomized clinical trial to examine the cardiovascular risks of Orexigen's weight-loss drug Contrave - inlicensed by Takeda for North American commercialization and development rights - prompted a 13-7 vote in favor of approval by the agency's Endocrinologic and Metabolic Drugs Advisory Committee Dec. 7

FDA Panel Backs Approval Of Orexigen's Obesity Drug Contrave

Promised post-market randomized clinical trial to assess cardiovascular risk tips the panel in favor of the naltrexone/bupropion combination.

FDA Panel Backs Approval Of Orexigen's Obesity Drug Contrave

Promised post-market randomized clinical trial to assess cardiovascular risk tips the panel in favor of the naltrexone/bupropion combination.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel